Gregory Moore
DAVITAAbout Gregory J. Moore, M.D., Ph.D.
Gregory J. Moore is an independent director at DaVita (DVA), serving since 2021, and currently chairs the Compliance and Quality Committee while also serving on the Nominating and Governance Committee . He is 60 years old and an engineer and practicing physician, board-certified in Diagnostic Radiology, Neuroradiology, and Clinical Informatics; he previously led Microsoft’s Health & Life Sciences AI and cloud efforts (2019–2023) and founded Google Cloud Healthcare (VP, 2016–2019) . He earned the NACD CERT Certificate in Cyber-Risk Oversight in 2024, strengthening board oversight of cybersecurity and compliance risks .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Microsoft Health and Life Sciences | Corporate Vice President; led AI and cloud product portfolio | 2019–2023 | Technology, AI/cloud product development oversight |
| Google Inc. | Vice President; founder and leader of Google Cloud Healthcare & Life Sciences globally | 2016–2019 | Built healthcare cloud platform; scaling data/AI infrastructure |
| Geisinger Health System | Chief Emerging Technology and Informatics Officer; Director, Institute of Advanced Application | Prior to 2016 | Applied informatics and emerging tech in provider operations |
| Academia (Stanford, Penn State, Wayne State) | Academic and clinical appointments | Prior to 2016 | Clinical/educational roles underpin healthcare expertise |
External Roles
| Organization | Exchange/Ticker | Role | Tenure | Committees/Notes |
|---|---|---|---|---|
| Fortive Corporation | NYSE: FTV | Director | Appointed Feb 2025 | Public company directorship; committee roles not disclosed |
| Olink Holding AB | — | Director | 2023–2024 | Board service until merger with Thermo Fisher Scientific |
| Hill-Rom Holdings, Inc. | — | Director | 2019–2021 | Board service until merger with Baxter International |
Board Governance
| Committee | Role | 2024 Meetings | Key Oversight Areas |
|---|---|---|---|
| Compliance and Quality | Chair | 4 | Healthcare regulatory compliance; program effectiveness; regulatory risk; ERM coordination |
| Nominating and Governance | Member | 4 | Board composition/refreshment; independence; governance policies; ESG oversight |
| Board of Directors (overall) | Independent director | Board met 5 times | Incumbent directors attended 97% of Board/committee meetings in 2024 |
- Independence: DaVita states all members of Audit, Compensation, and Nominating and Governance Committees are independent; members of Compliance and Quality are also independent . The Board determined eight of nine director nominees, including Dr. Moore, are independent under NYSE standards .
- Cyber governance: Audit Committee receives quarterly cybersecurity reports; Dr. Moore holds NACD CERT in cyber-risk oversight, bolstering board competency in cyber and privacy risk .
Fixed Compensation (Non‑Employee Director Program and Moore’s 2024 Actuals)
| Component | Policy Detail (2024) | Moore 2024 Actual |
|---|---|---|
| Annual cash retainer | $100,000, paid quarterly | Included in cash total $177,500 |
| Committee chair retainer | $50,000 for chairs of Audit, Compensation, Compliance & Quality, Nominating & Governance | Included in cash total $177,500 (Chair, Compliance & Quality) |
| Meeting fees | $2,500 for special Board meetings; $2,500 per committee meeting; $2,500 for Audit earnings‑related meetings | Included in cash total $177,500 |
| Expense reimbursement | Reasonable out‑of‑pocket expenses reimbursed | Policy applies |
| Per diem compensation | Permitted for significant time outside meetings at reasonable rates | Policy applies |
| Equity grants (DSIs) | Quarterly DSIs: $50,000 each on Mar 15, May 15, Aug 15, Nov 15 (prorated for new/retiring directors) | Stock awards $199,708 (aggregate grant‑date fair value) |
- 2024 Compensation Mix (Moore): Cash $177,500; Equity $199,708; Total $377,208 .
Performance Compensation
| Equity Award Type | Performance Metrics | Vesting/Grant Structure | Notes |
|---|---|---|---|
| Direct Stock Issuance (DSI) | None disclosed for directors; grants are service‑based | Granted quarterly; number of shares = $50,000 / closing price on grant date; prorated for partial service quarters | As of Dec 31, 2024, no non‑employee director had outstanding equity awards (e.g., options) |
- There are no director‑specific performance metrics (e.g., TSR/EBITDA) tied to director equity or cash compensation in the program; oversight of executive pay metrics resides with the Compensation Committee .
Other Directorships & Interlocks
| Relationship | Detail | Governance Implication |
|---|---|---|
| External boards | Fortive (current), Olink (prior), Hill‑Rom (prior) | Expands network and technology/healthcare insights; no DaVita‑disclosed commercial ties with these firms in independence review |
| Disclosed commercial relationships considered for independence | Cardinal Health (CEO director Jason Hollar) and Labcorp (CEO/Chair Adam Schechter) noted; immaterial and arm’s‑length; did not compromise independence of those directors | Dr. Moore not identified in commercial relationships review; no conflict flagged for him |
Expertise & Qualifications
- Technology/AI and healthcare domain expertise: Led health AI/cloud at Microsoft; founded Google Cloud Healthcare; clinical informatics credentials .
- Cyber risk oversight: NACD CERT Certificate in Cyber‑Risk Oversight (2024) .
- Skills matrix highlights: Strategic/M&A, Risk Management, Tech/Digital/Cyber, Healthcare/Provider/Payor, Human Capital/Compensation .
Equity Ownership
| Holder | Shares Beneficially Owned (as of Mar 31, 2025) | % of Shares Outstanding | Pledging/Hedging | Ownership Guidelines Compliance |
|---|---|---|---|---|
| Gregory J. Moore, M.D., Ph.D. | 6,103 | <1% (asterisk denotes less than 1%) | Hedging prohibited; pledging prohibited for directors under Insider Trading Policy | All non‑employee directors were in compliance as of Dec 31, 2024 |
- Ownership guideline threshold: Lesser of 25% of total pretax equity award value realized above $100,000 or five times annual cash retainer ($500,000) .
Governance Assessment
- Strengths
- Chairs Compliance & Quality in a heavily regulated healthcare business; committee oversees healthcare regulatory compliance effectiveness and risk (4 meetings in 2024) .
- Deep health technology and AI/cloud experience, plus NACD CERT in cyber oversight, aligning with DaVita’s privacy/cyber ERM processes and quarterly audit committee reporting .
- Independent director since 2021 with strong attendance across the Board overall (97% by incumbents in 2024; 26 total Board and committee meetings) .
- Equity ownership aligned via quarterly DSIs; all non‑employee directors in guideline compliance; hedging and pledging prohibited .
- Potential Risks/Conflicts
- External board at Fortive (appointed Feb 2025); no DaVita‑disclosed commercial relationship with Fortive, and Dr. Moore not cited in independence exceptions; monitor for future related party exposure .
- No individual attendance disclosure; reliance on aggregate attendance (97%)—consider monitoring committee‑specific attendance if disclosed in future proxies .
- RED FLAGS
- None disclosed specific to Dr. Moore in “Certain Relationships and Related Person Transactions”; proxy’s related party discussion centers on Berkshire share repurchase mechanism and does not identify him as a related person in any transaction .
- No Section 16(a) delinquency noted for Dr. Moore; late filings referenced for other individuals (Yale, Hearty) .
Overall signal: Dr. Moore brings highly relevant healthcare technology and cyber‑risk oversight to DaVita’s board while chairing the compliance function; independence, ownership alignment, and absence of related‑party issues in the proxy are supportive of investor confidence .